Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study

被引：0

作者：

Modest, D. P. ^{[1
]}

Tabernero, J. ^{[2
]}

Prager, G. ^{[3
]}

Fakih, M. ^{[4
]}

Ciardiello, F. ^{[5
]}

Van Cutsem, E. ^{[6
,7
]}

Elez, E. ^{[2
]}

Cruz, F. ^{[8
]}

Wyrwicz, L. ^{[9
]}

Stroyakovskiy, D. ^{[10
]}

Papai, Z. ^{[11
]}

Poureau, P. -G. ^{[12
]}

Liposits, G. ^{[13
]}

Cremolini, C. ^{[14
]}

Benhadji, K. ^{[15
]}

Bondarenko, I. ^{[16
]}

Skanji, D. ^{[17
]}

Roby, L. ^{[17
]}

Amellal, N. ^{[17
]}

Taieb, J. ^{[18
]}

机构：

[1] Charite, Hamatol Onkol & Tumorimmunol, Berlin, Germany

[2] Vall dHebron Univ Hosp & Inst Oncol VHIO, UVic UCC, IOB Quiron, Barcelona, Spain

[3] Med Univ Vienna, Dept Med 1, Vienna, Austria

[4] City Hope Comprehens Canc Ctr, Duarte, CA USA

[5] Univ Campania Luigi Vanvitelli, Dept Precis Med, Neapel, Italy

[6] Univ Hosp Leuven, Dept Digest Oncol, Herent, Belgium

[7] Katholieke Univ Leuven, Dept Digest Oncol, Herent, Belgium

[8] Nucleo Pesquisa & Ensino Rede Sao Camilo, Sao Paulo, Brazil

[9] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland

[10] Moscow City Oncol Hosp 62, Moscow, Russia

[11] Duna Med Ctr, Med Oncol, Budapest, Hungary

[12] Inst Cancerol, Brest, France

[13] Univ Southern Denmark, Dept Clin Res, Odense, Denmark

[14] Univ Pisa, Dept Translat Res & New Technol, Pisa, Italy

[15] Taiho Oncol Inc, Princeton, NJ USA

[16] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine

[17] Servier Int Res Inst, Suresnes, France

[18] Univ Paris Cite, Georges Pompidou European Hosp, SIRIC CARPEM, Paris, France

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V1019

引用

页码：157 / 158

页数：2

共 50 条

[41] Safety and efficacy of trifluridine/tipiracil plus bevacizumab in RAS mutated patients with metastatic colorectal cancer
Michalaki, Vasiliki
Theodosopoulos, Thedosios
Vezakis, Antonios
Papaconstantinou, Ioannis
Kontis, Ioannis
Dafnios, Nikolaos
Frangoulidis, George
Karandrea, Despina
Papadimitriou, Christos
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[42] Bevacizumab, irinotecan and biweekly trifluridine/tipiracil for pretreated metastatic colorectal cancer: MODURATE, a phase Ib study
Yamazaki, K.
Taniguchi, H.
Masuishi, T.
Kawakami, T.
Onozawa, Y.
Honda, K.
Tsushima, T.
Hamauchi, S.
Mori, K.
Yasui, H.
Muro, K.
ANNALS OF ONCOLOGY, 2022, 33 : S283 - S283
[43] Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study
Van Cutsem, E.
Danielewicz, I
Saunders, M. P.
Pfeiffer, P.
Argiles, G.
Borg, C.
Glynne-Jones, R.
Punt, C. J. A.
Van de Wouw, A. J.
Fedyanin, M.
Stroyakovskiy, D.
Kroening, H.
Garcia-Alfonso, P.
Wasan, H.
Falcone, A.
Kanehisa, A.
Egorov, A.
Aubel, P.
Amellal, N.
Moiseenko, V
ANNALS OF ONCOLOGY, 2020, 31 (09) : 1160 - 1168
[44] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
Gianluca Arrichiello
Alessandra Perrone
Stefania Napolitano
Giulia Martini
Vincenzo De Falco
Pasquale Incoronato
Maria Maddalena Laterza
Gaetano Facchini
Vincenzo Famiglietti
Valeria Nacca
Fernando Paragliola
Rossella Napolitano
Gabriella Suarato
Antonella Nicastro
Erika Martinelli
Davide Ciardiello
Fortunato Ciardiello
Teresa Troiani
Targeted Oncology, 2022, 17 : 635 - 642
[45] Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial
Oki, Eiji
Makiyama, Akitaka
Miyamoto, Yuji
Kotaka, Masahiko
Kawanaka, Hirofumi
Miwa, Keisuke
Kabashima, Akira
Noguchi, Tomohiro
Yuge, Kotaro
Kashiwada, Tomomi
Ando, Koji
Shimokawa, Mototsugu
Saeki, Hiroshi
Akagi, Yoshito
Baba, Hideo
Maehara, Yoshihiko
Mori, Masaki
CANCER MEDICINE, 2021, 10 (02): : 454 - 461
[46] Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study
Andre, Thierry
Falcone, Alfredo
Shparyk, Yaroslav
Moiseenko, Fedor
Polo-Marques, Eduardo
Csoszi, Tibor
Campos-Bragagnoli, Arinilda
Liposits, Gabor
Chmielowska, Ewa
Aubel, Paul
Martin, Lourdes
Fougeray, Ronan
Amellal, Nadia
Saunders, Mark P.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (02): : 133 - 144
[47] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
Arrichiello, Gianluca
Perrone, Alessandra
Napolitano, Stefania
Martini, Giulia
De Falco, Vincenzo
Incoronato, Pasquale
Laterza, Maria Maddalena
Facchini, Gaetano
Famiglietti, Vincenzo
Nacca, Valeria
Paragliola, Fernando
Napolitano, Rossella
Suarato, Gabriella
Nicastro, Antonella
Martinelli, Erika
Ciardiello, Davide
Ciardiello, Fortunato
Troiani, Teresa
TARGETED ONCOLOGY, 2022, 17 (06) : 635 - 642
[48] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
Kotani, D.
Kuboki, Y.
Yasuda, K.
Nakamura, Y.
Kawazoe, A.
Bando, H.
Taniguchi, H.
Shitara, K.
Yoshino, T.
ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
[49] Real-world efficacy and safety of trifluridine/tipiracil plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies
Martinez Lago, N.
Alonso de Castro, B.
Varela Ponte, R.
Reboredo Rendo, C.
Gomez-Randulfe Rodriguez, M.
Grana Suarez, B.
de la Camara Gomez, J.
Mateos Salvador, M.
Busto Fernandez, F.
Calleja Chucla, T.
Reboredo-Lopez, M.
ANNALS OF ONCOLOGY, 2021, 32 : S106 - S107
[50] The safety of trifluridine and tipiracil for the treatment of metastatic colorectal cancer
Martinez-Perez, Julia
Carmen Riesco-Martinez, M.
Garcia-Carbonero, Rocio
EXPERT OPINION ON DRUG SAFETY, 2018, 17 (06) : 643 - 650

← 1 2 3 4 5 →